Weiming Cai

Zhanjiang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Laminaria japonica polysaccharide mitigates acute neuroinflammation in cerebral ischemia-reperfusion injury through Csf3-modulated pathways.

Laminaria japonica polysaccharide mitigates acute neuroinflammation in cerebral ischemia-reperfusion injury through Csf3-modulated pathways.

Journal: Frontiers in immunology

Published: February 02, 2026

HLX and SLC25A20: Immunologic regulators bridging ankylosing spondylitis and uveitis via multi-omics integration and machine learning.

HLX and SLC25A20: Immunologic regulators bridging ankylosing spondylitis and uveitis via multi-omics integration and machine learning.

Journal: PloS one

Published: May 13, 2025

Reduced expression of cathepsin F predicts poor prognosis in patients with clear cell renal cell carcinoma.

Reduced expression of cathepsin F predicts poor prognosis in patients with clear cell renal cell carcinoma.

Journal: Scientific reports

Published: December 18, 2023

EFFICACY OF SUPPLEMENTAL HEMOADSORPTION THERAPY ON SEVERE AND CRITICAL PATIENTS WITH COVID-19: AN EVIDENCE-BASED ANALYSIS.

EFFICACY OF SUPPLEMENTAL HEMOADSORPTION THERAPY ON SEVERE AND CRITICAL PATIENTS WITH COVID-19: AN EVIDENCE-BASED ANALYSIS.

Journal: Shock (Augusta, Ga.)

Published: August 07, 2023

Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database.

Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database.

Journal: Scientific reports

Published: May 11, 2023

Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.

Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.

Journal: International journal of cancer

Published: October 08, 2021

G protein beta 3(GNβ3) C825T polymorphism and irritable bowel syndrome susceptibility: an updated meta-analysis based on eleven case-control studies.

G protein beta 3(GNβ3) C825T polymorphism and irritable bowel syndrome susceptibility: an updated meta-analysis based on eleven case-control studies.

Journal: Oncotarget

Published: September 06, 2017

HTR3A and HTR3E gene polymorphisms and diarrhea predominant irritable bowel syndrome risk: evidence from a meta-analysis.

HTR3A and HTR3E gene polymorphisms and diarrhea predominant irritable bowel syndrome risk: evidence from a meta-analysis.

Journal: Oncotarget

Published: June 12, 2017

Showing 1-8 of 8

Last Updated: 09/26/2026